Authors with [PD] after their names will also participate in a poster discussion session. 

Track A0: Diversifying the TB vaccine pipeline (general/other)

• Development of a human lung-liver-lymph node co-culture on a chip for the screening of tuberculosis vaccine candidates.
  Elly van Riet, TBVI (Netherlands) [PD]
• Investigating the role of Indoleamine dioxygenase in modulating immune responses to Mycobacterium tuberculosis
  Smriti Mehra, Texas Biomedical Research Institute (USA) [PD]
• A multi-antigen subunit vaccine improves BCG efficacy in mice and non-human primates
  Elena Stylianou, University of Oxford (UK) [PD]
• BAXERNA: Developing a next-generation mRNA vaccine against TB
  Lyudmila Kovalchuke, VIB-UGent (Belgium) [PD]
• Mucosal vaccination with cyclic dinucleotide adjuvants induces effective T cell homing and IL-17-dependent protection against Mycobacterium tuberculosis infection which may be autophagy
  Isabel D Lamb-Echegaray, UC Berkeley (USA) [PD]

Track A1: Mechanisms of biomarkers and protection

• Recombinant BCG vaccine rBCG-LTAK63 enhances autophagy in innate immune cells
  Ana Carolina de Oliveira Carvalho, Instituto Butantan (Brazil) [PD]
• Immunogenicity and protection against tuberculosis following intravenous immunization with auxotrophic or irradiated BCG in rhesus macaques
  Patricia A Darrah,  National Institutes of Health (USA)
• Coexpression network analysis-based identification of critical genes and regulatory factors driving inter-individual variation in response to Mycobacterium tuberculosis infection.
  Oluwaseun Oluwatosin Taofeek, Department of Chemical Sciences, Crescent University (Nigeria)

Track A4: Human challenge model / Controlled human infection model

• Characterising lung mucosal and systematic immune response in an aerosol BCG human challenge model using single cell sequencing
  Shuailin Li, University of Oxford (UK) [PD]
• A phase I single site open label clinical trial for the development of a human BCG challenge model to assess TB drugs and vaccines
  Elizabeth Church, Fred Hutchinson Cancer Center (USA) [PD]
• Prior BCG vaccination protects against subsequent aerosol BCG challenge in UK adults
  Iman Satti, University of Oxford (UK) [PD]

Track A5: Preclinical development

• A Mycobacterium tuberculosis variable antigen vaccine induces infection tolerance
  Zach P. Howard, University of California, San Francisco (USA) [PD]
• T cell responses to TITAN mRNA vaccine antigens in adults with Mtb infection and TB disease
  Monika M. Looney, University of Cape Town (South Africa)
• Generation and testing of human-ready, rationally attenuated and efficacious live M. tuberculosis vaccine candidates to protect against tuberculosis and TB/HIV co-infection
  Garima Arora, Texas Biomedical Research Institute (USA)
• Developing a new generation mucosal TB vaccine
  Chunlin Xin, CanSino Biologics Inc. (China)
• Development of TB recombinant mycobacterial vaccine without antimicrobial resistance marker
  Ana Paula Junqueira-Kipnis, Federal University of Goiás (Brazil)
• Developing a Novel mRNA vaccine for tuberculosis: Insights from in silico analysis
  Juliana Gil Melgaço, Bio-Manguinhos/Fiocruz (Brazil)
• Prevention of tuberculosis in nonhuman primates by an attenuated Mycobacterium tuberculosis vaccine
  Deepak Kaushal, Texas Biomedical Research Institute (USA)

Track A6: Optimizing animal models

• Establishing a humanized mouse model to mimic human tuberculosis pathology for in vivo immunotherapy research
  Monalisa Martins Trentini, Instituto Butantan (Brazil) [PD]
• Prior Mycobacterium tuberculosis exposure enhances the efficacy of subunit vaccination
  Sara B. Cohen, Seattle Children's Research Institute (USA)
• Microevolution of BCG vaccine strain after inoculation in susceptible individuals may lead to increased virulence of mycobacteria
  Bárbara A. Barcelos Rangel, State University of Northern Fluminense (Brazil)
• Refinement of aerobiology techniques for the pre-clinical evaluation of interventions against respiratory pathogens
  Rebecca Winsbury, UK Health Security Agency (UK)

Track B1: Clinical trials

• Community consensus and call to action on inclusion of pregnant and breastfeeding women and persons in TB vaccine trials
  Edna Tembo, Coalition of Women Living with HIV/AIDS (COWLHA) (Malawi) [PD]
• The ethics of including persons deprived of liberty in tuberculosis vaccine trials
  Monica Queiroz Ferreira de Magalhaes, Rutgers University (USA) [PD]
• Perceptions of the incarcerated population regarding tuberculosis research and vaccines
  Crhistinne C M Gonçalves, Faculdade de Medicina da Universidade Federal do Mato Grosso do Sul (Brazil) [PD]
• MTBVAC202: Defining the dose for a multi-centre Phase 3 efficacy trial in infants
  Michele Tameris, University of Cape Town (South Africa)
• MTBVAC dose-finding study, a Phase 1b/2a randomized, controlled, double-blind clinical trial, in young adults in South Africa, with and without sensitization to Mycobacterium tuberculosis
  Angelique Luabeya Kany Kany, University of Cape Town, South Africa

Track B4: Correlates of protection

• mRNA signatures measured prior to H56:IC31 vaccination predict TB relapse in HIV negative adults successfully treated for drug-susceptible pulmonary TB
  Simon C Mendelsohn, University of Cape Town (South Africa) [PD]

B7: Community engagement in TB vaccine trials

• Challenges in recruiting neonates for a phase III TB vaccine trial and mitigations taken: Lessons learned for community engagement in Mbeya, Tanzania
  Doreen Pamba, National Institute for Medical Research (Tanzania)

Tracks C0, C2, C3: Ensuring public health impact (general/other), Delivery systems, Vaccine value proposition

• A study of knowledge and experiences about tuberculosis infection amongst persons who use and inject drugs (PWUIDs) in Lagos, Oyo, Ogun States -South Western Nigeria.
  James Osamudiame Eghaghe, Nigeria Network of People Who Use Drugs (Nigeria) [PD]
• Enhancing community engagement in tuberculosis vaccine delivery among key populations: A qualitative study
  Martha N Nyakambi, PHDA (Kenya) [PD]
• Potential implications of reduced tuberculosis vaccine efficacy in those with undernutrition on overall vaccine impact in India
  Rebecca A. Clark, London School of Hygiene and Tropical Medicine (UK)
• The implications of using different time horizons when evaluating investment to prevent infectious disease
  Rebecca A Clark, London School of Hygiene and Tropical Medicine (UK)

Track C4: Barriers and enablers of vaccine uptake

• Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan 
  Rupali J Limaye, Johns Hopkins Bloomberg School of Public Health (USA) [PD]
• Insights into TB vaccine acceptability among adolescents in Khayelitsha through a public engagement lens
  Anastasia Sideris Koch, Eh!woza (South Africa)
• Acceptability of a novel TB vaccine or BCG booster among adults, caretakers of adolescents and adolescents in Manhiça District, southern Mozambique.
  Lisa Marie Cramner, Emory University (USA)